Merck & Co – known as MSD outside of the US and Canada – and Cyprumed have entered into a partnership aimed at developing ...

Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

Monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer recurrence, a new study shows.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Screening tests are critical in early detection because they can find cancer before symptoms appear, when treatment is more ...

Growth Drivers include demand for protein-based drugs, rise in chronic disease prevalence, precision medicine expansion, biotech advancements, and AI-driven design tools.Dublin, April 14, 2025 (GLOBE ...

Merck Life Science South Africa, a leading science and technology company, is excited to announce its participation as a bronze sponsor at Analytica Lab Africa 2025. This major trade fair for ...

Mark T. Esser, a pharmaceutical researcher and executive, brings scientific expertise and leadership experience to his new ...